TOR1B

Across TCGA pan-cancer cohorts, TOR1B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TOR1B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TOR1B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TOR1B is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

HNSC, CCRCC, and PDAC are the cancer types where TOR1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TOR1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+0.727	<.001	11	view →
CCRCC	All	All	+0.172	<.001	11	view →
PDAC	Male	All	+0.278	.005	4	view →
LSCC	Female	II,III,IV	−0.293	<.001	2	view →
COAD	Female	All	−0.141	.029	2	view →
LUAD	All	All	−0.084	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TOR1B–HNSC

Open the HNSC breakdown →